Identified two proteins as probable biomarkers of the clinical efficacy of immunotherapy with allergens.
Identified two proteins as probable biomarkers of the clinical efficacy of immunotherapy with allergens. -the molecular changes in the field of dendritic cells may indicate early how responds to allergen immunotherapy Agency -the study, carried out by Stallergenes, has been published by the Journal of Allergy and Clinic Immunology last month Antony (France), may 2012.- two proteinsC1Q and STAB1, expressed by various types of regulatory dendritic cells (DCs), can be employed to measure how responds to the Agency in the early stages of allergen immunotherapy. This is the main conclusion of a study conducted by researchers from Stallergenes, published last month Journal of Allergy and Clinic Immunology (JACI). To obtain the expression of markers researchers used methodology as quantitative PCR (polymerase chain reaction) in mononuclear cells of peripheral blood (PBMCs) of 79 patients with allergy to pollen of grasses. These patients participated in a clinical study, controlled double-blind, placebo, to assess the efficacy of sublingual tablets in a camera’s exposure to allergens for a period exceeding four months. In the article published by JACI authors explain how discovered that the expression of CQ1 and STAB1 increased significantly in the PBMCs of subjects responded positively to the treatment of allergen immunotherapy, versus those who did not or were treated with placebo. Thus, the researchers conclude that these two proteins may be biomarkers for the early efficacy of allergen immunotherapy. Once...
Read More